New Delhi, Nov 27 (IANS) The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report on Wednesday. OUD is a chronic neurological disorder that causes compulsive, repeated use of opioid drugs, leading to prolonged self-administration. The company recently terminated the development of AZD4041 during a Phase II trial, as the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal. The report by GlobalData, a data and analytics company, showed that six out of the seven agents currently in late-st
Hence then, the article about failure of astrazeneca s opioid drug trial a major blow for addiction medications report was published today ( ) and is available onNews room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Failure of AstraZeneca’s opioid drug trial a major blow for addiction medications: Report )